WT1xCD3x4-1BB T cell engager therapeutic: - Biocytogen Pharmaceuticals/CtM Biotech
Alternative Names: WT1-TOPAbodyLatest Information Update: 09 Feb 2024
At a glance
- Originator Beijing Biocytogen; CtM Bio
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins; Trispecific antibodies
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours